SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458508092809v1
14/8/1044    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Miyazaki, Y
Right arrow Articles by Onoé, K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyazaki, Y
Right arrow Articles by Onoé, K
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

research-article

Expansion of CD4+CD28– T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis

Y Miyazaki

Division of Immunobiology, Research Section of Pathophysiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan

K Iwabuchi

Division of Immunobiology, Research Section of Pathophysiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan

S Kikuchi

Department of Neurology, Sapporo Minami National Hospital, Sapporo, Japan

T Fukazawa

Sapporo Neurology Clinic, Sapporo, Japan

M Niino

Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

M Hirotani

Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

H Sasaki

Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

K Onoé

Division of Immunobiology, Research Section of Pathophysiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan

CD4+ T cells that lack surface expression of the CD28 co-stimulatory molecule (CD4+CD28 T cells) were expanded in peripheral blood of patients with multiple sclerosis (MS) [5.20 ± 1.67% vs 13.00 ± 2.68% (healthy controls (HC) versus patients with MS)]. Both the CD4+CD28+ and CD4+CD28 T-cell populations of patients with MS produced higher levels of interferon (IFN)-{gamma} compared with those in HC. In particular, the proportion of IFN-{gamma}+ cells among CD4+CD28 T cells from patients with MS was considerably high. However, expression of co-stimulatory molecules including inducible costimulator (ICOS), activating natural killer receptors, or members of tumor necrosis factor receptor family that replace CD28 in CD4+CD28 T cells of patients with MS could not be identified. A unique subpopulation bearing the CD45RAhighCCR7 phenotype was identified among the CD4+CD28 T cells of some patients with MS. Because only MS samples contained this CD45RAhighCCR7 population attributed to terminally differentiated effector memory cells and lacked naive CD45RAhighCCR7+ cells, we suggest that CD4+CD28 T cells of patients with MS represent a cell population which is in more differentiated state than healthy subjects. In patients treated with IFN-β-1b, IFN-{gamma} production from CD4+CD28+ T cells was suppressed compared with that in untreated patients. On the contrary, in the CD4+CD28 population, production of IFN-{gamma} in IFN-β-1b-treated patients was not significantly suppressed compared with that in untreated patients with MS. Thus, an additional treatment strategy that specifically targets this cell population may enhance the beneficial effect of IFN-β on MS.

Key Words: CD4+CD28– T cells • co-stimulation • interferon-β • interferon-{gamma} • interleukin-17 • multiple sclerosis

This version was published on September 1, 2008

Multiple Sclerosis, Vol. 14, No. 8, 1044-1055 (2008)
DOI: 10.1177/1352458508092809


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Neurosci.Home page
I. Racz, X. Nadal, J. Alferink, J. E. Banos, J. Rehnelt, M. Martin, B. Pintado, A. Gutierrez-Adan, E. Sanguino, N. Bellora, et al.
Interferon-{gamma} Is a Critical Modulator of CB2 Cannabinoid Receptor Signaling during Neuropathic Pain
J. Neurosci., November 12, 2008; 28(46): 12136 - 12145.
[Abstract] [Full Text] [PDF]



Advertisement